Journal of extracellular vesicles

Hybrid Tiny Particles for Efficient mRNA Loading and Delivery

Updated

Abstract

Essence

Hybrid created by fusing EVs with improved mRNA loading and functional delivery.

Evidence

This preclinical delivery-platform study used particle characterization, intracellular trafficking analysis, and in vivo testing to show , functional mRNA delivery, and predominantly splenic extrahepatic distribution.

Caveat

The results establish a delivery platform rather than clinical benefit, with evidence limited to mechanistic and in vivo distribution experiments.

Simplified

Key numbers

75%
Percentage of RNA encapsulated in produced under optimal conditions.
90%
at High Dose
Percentage of viable cells after treatment with formulations at high RNA doses.
N/A
Predominant mRNA Delivery to Spleen
Functional biodistribution pattern of -delivered mRNA in vivo.

Key figures

FIGURE 1
Comparison of () and (HEV) loaded with mRNA
Highlights larger size and higher mRNA loading in compared to EVs, spotlighting improved delivery potential
JEV2-14-e70201-g004
  • Panel A
    Schematic of HEV production by fusing EVs with () containing mRNA
  • Panel B
    Mean size of EV and HEV measured by ; HEV appears larger than EV
  • Panel C
    images showing EV and HEV dual-labeled with anti-CD63 (EV marker) and anti- (LNP component); HEV shows visible gold particle labeling for both markers
  • Panel D
    detecting classical EV markers Alix, Tsg101, CD63, CD81 in EV and HEV; β-actin used as loading control
  • Panel E
    dot plots of side scatter versus fluorescence showing Cy5-positive particles in HEV but not EV
  • Panel F
    Size distribution plots of total particles (black line) and Cy5-positive subpopulation (red line) in EV and HEV samples
  • Panel G
    Bar graph showing percentage of Cy5-positive particles; HEV has significantly higher percentage than EV
  • Panel H
    Bar graph of (MFI) of Cy5 in total particle populations; HEV shows higher MFI than EV
FIGURE 2
, , and nanoparticle compositions analyzed by Raman spectroscopy.
Highlights compositional differences and incorporation of LNP components in compared to and .
JEV2-14-e70201-g006
  • Panel A
    plot clustering nanoparticles by showing LNP, EV, and HEV groups distinctly clustered.
  • Panel B
    Raman spectra signals for LNP, EV, and HEV with peaks indicating ionizable lipid, polymer, cholesterol, and proteins.
  • Panel C
    Violin plots comparing MC3, PEG, cholesterol, and protein components in LNP, EV, and HEV with median and range shown.
FIGURE 3
Optimization of hybrid extracellular vesicle () production parameters affecting particle and RNA recovery, encapsulation, and size distribution
Highlights how varying particle concentration and : ratio affects RNA loading and particle recovery in hybrid vesicles
JEV2-14-e70201-g005
  • Panel A
    Schematic of experimental setups for HEV production optimization: Setup A varies particle concentration; Setup B varies EV:LNP particle ratio
  • Panel B
    Particle and RNA recovery efficiency for HEV C1, C2, C3 (different particle concentrations) versus control; HEV C2 shows higher RNA recovery than control
  • Panel C
    for HEV C1, C2, C3 and controls; HEV C2 and C3 show significantly higher encapsulation than control and LNP
  • Panel D
    Size distribution of nanoparticles in Setup A groups; HEV groups show size peaks around 100-300 nm, differing from LNP and EV controls
  • Panel E
    Particle and RNA recovery efficiency for HEV R1, R2, R3, R4 (different EV:LNP ratios); HEV R4 shows highest RNA recovery, HEV R2 and R3 show higher particle recovery
  • Panel F
    RNA encapsulation efficiency for HEV R1-R4 and LNP; encapsulation remains similar across HEV groups and LNP
  • Panel G
    Size distribution of nanoparticles in Setup B groups; HEV groups show size peaks around 100-300 nm, distinct from LNP and EV controls
  • Panel H
    RNA amount per particle normalized by particle number; HEV R4 has significantly higher RNA per particle than other groups
  • Panel I
    Correlation between RNA molecules per particle and LNP proportion in HEV formulations; strong positive correlation (R²=0.96)
FIGURE 4
Cell growth and viability after treatment with () at different RNA doses
Highlights higher and growth with HEVs compared to at high RNA doses, emphasizing HEV tolerability.
JEV2-14-e70201-g002
  • Panel A
    over 72 hours after treatment with HEVs at 10, 100, and 1000 ng RNA per well; at 1000 ng, HEV treatments appear to reduce confluence compared to vehicle control.
  • Panel B
    (absorbance) after 72 hours with HEVs at 10, 100, and 1000 ng RNA per well; absorbance is visibly lower for LNP at 100 and 1000 ng compared to HEV groups.
  • Panel C
    Cell viability percentages after 72 hours with HEVs at 10, 100, and 1000 ng RNA per well; viability is significantly reduced for LNP and HEV R4 at 1000 ng compared to other HEV ratios and vehicle.
FIGURE 5
Functional delivery and expression of Cre mRNA by in cells
Highlights higher expression intensity in -treated cells compared to , spotlighting delivery efficiency differences
JEV2-14-e70201-g003
  • Panel A
    Schematic of Cre-Lox reporter system where Cre recombination activates EGFP and expression in cells
  • Panels B and C
    Percentage of EGFP-positive cells and () of EGFP after 72 h treatment with HEVs or LNP at varying RNA doses; LNP shows higher EGFP-positive percentage and MFI at 100 ng RNA per well
  • Panel D
    Microscopic images of EGFP fluorescence in cells treated with vehicle, LNP, or HEVs (R1-R4) at 100 ng RNA per well for 72 h; LNP and HEVs show visible EGFP expression, vehicle does not
  • Panel E
    Kinetics of total integrated EGFP fluorescence intensity per well over 72 h for vehicle, LNP, and HEVs (R1-R4); LNP and HEVs show increasing EGFP intensity over time, vehicle remains at baseline
1 / 5

Full Text

What this is

  • Hybrid (HEVs) combine the benefits of () and () for mRNA delivery.
  • This study presents a method to load mRNA into HEVs via low pH-induced fusion, maintaining EV characteristics.
  • HEVs demonstrated effective mRNA delivery in vitro and in vivo, with a notable ability to induce .

Essence

  • HEVs effectively load and deliver mRNA by merging the properties of and . This approach enhances intracellular delivery and functional distribution, particularly to the spleen.

Key takeaways

  • HEVs achieved a high RNA encapsulation efficiency of approximately 75% when produced under optimal conditions. This efficiency surpasses traditional methods for loading mRNA into .
  • HEVs demonstrated excellent cell tolerability, with minimal impact on cell growth and viability across various doses, unlike which exhibited dose-dependent toxicity.
  • In vivo studies revealed that HEVs delivered mRNA predominantly to the spleen, contrasting with which favored liver delivery. This suggests a potential for targeted therapeutic applications.

Caveats

  • The study's findings on HEV biodistribution and safety profiles are based on a limited number of animal models, necessitating further validation in diverse biological contexts.
  • The delivery efficiency of HEVs was lower than that of under similar conditions, indicating that further optimization is needed for practical applications.

Definitions

  • extracellular vesicles (EVs): Membrane-bound vesicles secreted by cells that carry bioactive molecules, facilitating intercellular communication.
  • lipid nanoparticles (LNPs): Nanoparticles composed of lipids used to encapsulate and deliver nucleic acids, such as mRNA, to target cells.
  • endosomal escape: The process by which internalized materials exit endosomes to enter the cytoplasm, crucial for effective delivery of therapeutic agents.

Simplified

Funding

Competing interests

X.W., M.J.M., K.F., A.M., A.M.S., F.K., L.H. and N.D. are or were employees of AstraZeneca. All remaining authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free